JP2005508910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508910A5 JP2005508910A5 JP2003530275A JP2003530275A JP2005508910A5 JP 2005508910 A5 JP2005508910 A5 JP 2005508910A5 JP 2003530275 A JP2003530275 A JP 2003530275A JP 2003530275 A JP2003530275 A JP 2003530275A JP 2005508910 A5 JP2005508910 A5 JP 2005508910A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005843 halogen group Chemical group 0.000 claims 72
- 125000000217 alkyl group Chemical group 0.000 claims 68
- 125000003545 alkoxy group Chemical group 0.000 claims 62
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- -1 heteroaralkoxy Chemical group 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- SVSARCCKBMZNMR-UHFFFAOYSA-N [1-[2-[methyl-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethyl]amino]ethyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1CCN(C)CCN1C=CC(=C[NH+]=O)C=C1 SVSARCCKBMZNMR-UHFFFAOYSA-N 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims 4
- 229940124639 Selective inhibitor Drugs 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000005354 acylalkyl group Chemical group 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000005466 alkylenyl group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000004967 formylalkyl group Chemical group 0.000 claims 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004995 haloalkylthio group Chemical group 0.000 claims 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000000324 neuroprotective effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(*)(*)CC(*)(*)*=*CNC(*)=N Chemical compound *C(*)(*)CC(*)(*)*=*CNC(*)=N 0.000 description 5
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/961,521 US20030119826A1 (en) | 2001-09-24 | 2001-09-24 | Neuroprotective treatment methods using selective iNOS inhibitors |
| PCT/US2002/030214 WO2003026638A1 (en) | 2001-09-24 | 2002-09-24 | Neuroprotective treatment methods using selective inos inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508910A JP2005508910A (ja) | 2005-04-07 |
| JP2005508910A5 true JP2005508910A5 (enExample) | 2006-01-05 |
Family
ID=25504581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530275A Pending JP2005508910A (ja) | 2001-09-24 | 2002-09-24 | 選択的ｉＮＯＳ阻害剤を用いる神経保護的な治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030119826A1 (enExample) |
| EP (1) | EP1429752A1 (enExample) |
| JP (1) | JP2005508910A (enExample) |
| KR (1) | KR20040039394A (enExample) |
| CN (1) | CN1556698A (enExample) |
| AU (1) | AU2002327042A2 (enExample) |
| BR (1) | BR0212989A (enExample) |
| CA (1) | CA2455989A1 (enExample) |
| IL (1) | IL161005A0 (enExample) |
| MX (1) | MXPA04002710A (enExample) |
| PL (1) | PL371774A1 (enExample) |
| WO (1) | WO2003026638A1 (enExample) |
| ZA (1) | ZA200402288B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| CN107176923A (zh) * | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| CA2736091A1 (en) * | 2008-09-03 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| CN105616410A (zh) * | 2009-07-30 | 2016-06-01 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
| ES2731052T3 (es) * | 2009-08-10 | 2019-11-13 | Active Biotech Ab | Tratamiento de la enfermedad de Huntington usando laquinimod |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100835265B1 (ko) * | 2000-03-24 | 2008-06-09 | 파마시아 코포레이션 | 산화 질소 신타아제 억제제로 유용한 아미디노 화합물 및그들의 염 |
| AR032318A1 (es) * | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
-
2001
- 2001-09-24 US US09/961,521 patent/US20030119826A1/en not_active Abandoned
-
2002
- 2002-09-24 WO PCT/US2002/030214 patent/WO2003026638A1/en not_active Ceased
- 2002-09-24 AU AU2002327042A patent/AU2002327042A2/en not_active Abandoned
- 2002-09-24 IL IL16100502A patent/IL161005A0/xx unknown
- 2002-09-24 JP JP2003530275A patent/JP2005508910A/ja active Pending
- 2002-09-24 BR BR0212989-2A patent/BR0212989A/pt not_active IP Right Cessation
- 2002-09-24 EP EP02761804A patent/EP1429752A1/en not_active Withdrawn
- 2002-09-24 KR KR10-2004-7004170A patent/KR20040039394A/ko not_active Withdrawn
- 2002-09-24 MX MXPA04002710A patent/MXPA04002710A/es unknown
- 2002-09-24 CN CNA028185935A patent/CN1556698A/zh active Pending
- 2002-09-24 PL PL02371774A patent/PL371774A1/xx not_active Application Discontinuation
- 2002-09-24 CA CA002455989A patent/CA2455989A1/en not_active Abandoned
-
2004
- 2004-03-23 ZA ZA200402288A patent/ZA200402288B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508910A5 (enExample) | ||
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| US20070021352A1 (en) | Prevention and treatment of hearing disorders | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| JP2007535496A5 (enExample) | ||
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JP2007525510A5 (enExample) | ||
| EP1568361A3 (en) | Sustained-release pharmaceutical composition containing tamsulosin | |
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| WO2023129958A3 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
| RU2003118411A (ru) | Кристаллические производные 1-метилкарбапенема | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| RU2000122435A (ru) | Производные индола и фармацевтические композиции, включающие их | |
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| TW200502222A (en) | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| JP2007525521A5 (enExample) | ||
| ATE361749T1 (de) | Benzthiazol-3 oxide zur behandlung von proliferativen störungen | |
| JP2005532269A5 (enExample) | ||
| CA2441309A1 (en) | Biguanide derivatives | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| JP2009523142A5 (enExample) | ||
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| JP2008538211A5 (enExample) | ||
| US20070123555A1 (en) | Prevention and treatment of hearing disorders |